Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Nathalie Britzen‐Laurent

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0494-7117; OpenAlex author ID A5080373737. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Co-author DOI 10.3390/cancers17193181↗
  2. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  3. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Co-author DOI 10.3390/cancers15194842↗
  4. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  5. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer. Last author DOI 10.3389/fcell.2022.975684↗
  6. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Co-author DOI 10.3390/cancers14020326↗
  7. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/cancers14133152↗
  8. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Co-author DOI 10.3390/cancers15010241↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Grützmann · 8 shared papers, 2022–2025 · strength 1.28
  2. Christian P. Pilarsky · 8 shared papers, 2022–2025 · strength 1.28
  3. Hai Yang · 5 shared papers, 2022–2024 · strength 0.73
  4. Bin Lan · 4 shared papers, 2022–2025 · strength 0.64
  5. Nils Cordes · 2 shared papers, 2022–2025 · strength 0.37
  6. Jinping Zhang · 2 shared papers, 2023–2024 · strength 0.33
  7. Duo Yun · 2 shared papers, 2022–2024 · strength 0.31
  8. Hang He · 2 shared papers, 2022–2024 · strength 0.30
  9. Shuman Zhang · 2 shared papers, 2022–2024 · strength 0.27
  10. Debabrata Mukhopadhyay · 2 shared papers, 2022–2024 · strength 0.27
  11. Andrew Victor Biankin · 2 shared papers, 2022–2024 · strength 0.27
  12. Deliang Fu · 1 shared paper, 2022 · strength 0.15
  13. Yanxi Lu · 1 shared paper, 2024 · strength 0.15
  14. Eva Lentsch · 1 shared paper, 2024 · strength 0.15
  15. Marc P. Stemmler · 1 shared paper, 2024 · strength 0.15
  16. Hao Yang · 1 shared paper, 2024 · strength 0.15
  17. Bin Liu · 1 shared paper, 2022 · strength 0.14
  18. Siyuan Zeng · 1 shared paper, 2022 · strength 0.13
  19. Peter J. Bailey · 1 shared paper, 2022 · strength 0.13
  20. Daniel Schreyer · 1 shared paper, 2022 · strength 0.13
  21. David Kuang-Fu Chang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.